{"id":"muc16","name":"MUC16 (CA-125)","symbol":"MUC16","route":"/targets/muc16/","asOf":"2026-09-21","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15582","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181143","uniprot":"https://www.uniprot.org/uniprotkb/Q8WXI7/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q8WXI7","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3580482","open-targets":"https://platform.opentargets.org/target/ENSG00000181143","civic":"https://civicdb.org/genes/94025/summary","oncokb":"https://www.oncokb.org/gene/MUC16","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MUC16","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=MUC16","depmap":"https://depmap.org/portal/gene/MUC16?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000181143-MUC16","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/94025","omim":"https://www.omim.org/entry/606154"}],"products":[{"id":"ubamatamab","name":"Ubamatamab","status":"phase-2","modality":"Bispecific T-cell engager (MUC16×CD3)","route":"/drugs/ubamatamab/"}],"trials":[{"id":"nct07154290","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT07154290","phase":"2","status":"recruiting"},{"id":"nct07480954","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","nct":"NCT07480954","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["regeneron"],"keyPapers":["paper-zhu-clin-transl-sci"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}